Infectious diseases are caused by a wide range of bacterial, viral, fungal, and parasitic pathogens.

Rapid and accurate identification of infection is essential for selecting appropriate treatment and preventing transmission.

Traditional diagnostic approaches often depend on culture, microscopy, antigen detection, or serological testing.

Although these methods remain important, they can have limitations related to sensitivity, specificity, turnaround time, and pathogen viability.

Molecular biomarkers offer new opportunities for detecting infection and characterizing disease processes.

These biomarkers can originate directly from pathogens or from the host response to infection.

Types of Molecular Biomarkers

Molecular biomarkers used in infectious disease research can be broadly divided into pathogen-derived and host-derived biomarkers.

Pathogen-Derived Nucleic Acids

DNA and RNA from infectious organisms are among the most widely used molecular biomarkers.

Polymerase chain reaction can detect specific pathogen sequences with high analytical sensitivity.

Multiplex molecular assays can simultaneously detect several potential pathogens from a single clinical sample.

This can be particularly useful when clinical symptoms overlap between different infections.

Detection of pathogen nucleic acids may also be valuable when organisms are difficult to culture or when antimicrobial treatment has already been initiated.

Cell-Free Microbial DNA

Cell-free DNA fragments released from microorganisms may circulate in blood and other biological fluids.

Detection of microbial cell-free DNA has attracted interest because it may identify pathogens that are difficult to recover through conventional culture.

Sequencing-based approaches can potentially detect multiple organisms within complex clinical samples.

This approach may be especially useful in selected cases of bloodstream infection and infections involving normally sterile tissues.

However, interpretation can be complicated by contamination and detection of microbial DNA that does not necessarily indicate active infection.

Host-Derived Biomarkers

The host responds to infection through complex immune and inflammatory pathways.

Changes in circulating cytokines, acute-phase proteins, immune-cell gene expression, and metabolic profiles may provide information about infection.

Host biomarkers may be particularly valuable when direct pathogen detection is difficult.

They can also provide information about the severity of the host response.

However, many host biomarkers are not specific to infection and may also increase during autoimmune disease, trauma, or other inflammatory conditions.

Cytokines and Inflammatory Biomarkers

Cytokines are important mediators of the immune response.

Interleukin-6, interleukin-8, tumor necrosis factor-alpha, and other inflammatory mediators can change during infectious disease.

Their concentrations may provide information about systemic inflammation and disease severity.

The diagnostic value of individual cytokines is often limited because similar changes can occur in non-infectious inflammatory conditions.

For this reason, combinations of multiple biomarkers may provide greater diagnostic value than a single cytokine.

MicroRNAs as Diagnostic Biomarkers

MicroRNAs are small non-coding RNA molecules that regulate gene expression.

Infectious diseases can alter host microRNA expression through immune activation, cellular stress, and pathogen-host interactions.

Some microRNAs are stable in circulating biological fluids and can potentially be measured using molecular techniques.

Disease-associated microRNA profiles may therefore provide information about infection and host response.

However, standardization of sample collection, RNA extraction, normalization, and analytical methods remains important.

Host Gene Expression Signatures

Infection can produce characteristic changes in host gene expression.

RNA sequencing and other transcriptomic approaches can identify patterns associated with specific infections or groups of pathogens.

Host transcriptional signatures may potentially distinguish bacterial from viral infections.

This could have clinical value because inappropriate antimicrobial use often occurs when the etiology of an infection is uncertain.

Further validation is required before transcriptomic signatures can be routinely implemented in clinical laboratories.

Molecular Biomarkers in Major Infectious Diseases

Advanced Molecular Technologies

Recent technological developments have expanded infectious disease biomarker research.

Next-generation sequencing can detect and characterize nucleic acids from multiple organisms.

Metagenomic sequencing is particularly attractive because it does not necessarily require prior knowledge of the suspected pathogen.

Proteomic approaches can identify pathogen- or host-derived proteins associated with infection.

Metabolomic technologies can identify changes in small molecules associated with immune activation and microbial metabolism.

Combining these technologies may produce comprehensive molecular profiles of infectious diseases.

This article was prepared as a concise narrative review of scientific literature concerning emerging molecular biomarkers for infectious disease diagnosis.

Relevant research addressing pathogen-derived nucleic acids, cell-free microbial DNA, host inflammatory biomarkers, microRNAs, transcriptomic signatures, proteomic markers, and metabolomic profiles was considered.

The available evidence was synthesized to describe emerging diagnostic approaches and their potential clinical applications.

Results

The reviewed evidence indicates that molecular biomarkers can provide important information about both the presence of pathogens and the host response to infection.

Pathogen-derived nucleic acids provide direct evidence of microbial presence, while host-derived biomarkers can characterize immune activation and disease severity.

Advances in sequencing and multi-omics technologies have expanded the ability to identify previously unrecognized molecular signatures.

Combining multiple biomarkers may improve diagnostic accuracy compared with reliance on individual markers.

The development of rapid molecular biomarkers has the potential to transform infectious disease diagnosis.

Traditional culture remains essential for many bacterial infections, particularly when antimicrobial susceptibility testing is required.

However, culture may require considerable time and can fail when organisms are difficult to grow or when patients have already received antimicrobial therapy.

Molecular approaches can provide much faster information.

Pathogen nucleic acid detection is particularly useful for infections in which rapid identification influences treatment decisions.

Host-response biomarkers provide a complementary strategy.

Instead of detecting the pathogen directly, they identify molecular changes produced by the infected host.

This approach may be useful when pathogen burden is low or when direct detection is technically difficult.

A major challenge is specificity.

Inflammatory biomarkers may be elevated in both infectious and non-infectious conditions.

Therefore, combinations of biomarkers may provide better discrimination.

Artificial intelligence and machine-learning approaches may assist in identifying complex biomarker patterns within large molecular datasets.

The integration of molecular biomarkers with clinical information, imaging, and conventional laboratory tests could support more accurate diagnosis and risk stratification.

Clinical Applications and Future Perspectives

Molecular biomarkers may have several potential applications.

They could support rapid pathogen identification, distinguish different infection categories, assess disease severity, predict clinical outcomes, and monitor treatment response.

Future diagnostic platforms may combine pathogen sequencing with host-response profiling.

Point-of-care molecular technologies may also allow biomarker testing outside conventional laboratories.

For successful clinical implementation, however, assays must demonstrate high analytical accuracy, reproducibility, cost-effectiveness, and clinical utility.

Large prospective studies are needed to validate emerging biomarkers across diverse patient populations.

Limitations

Several challenges currently limit widespread clinical use of emerging molecular biomarkers.

Biomarker concentrations may vary with age, immune status, disease stage, medication exposure, and sample type.

Molecular detection of pathogen nucleic acids does not always demonstrate active infection.

Similarly, host-response biomarkers may be affected by non-infectious inflammatory conditions.

Differences in laboratory platforms and data-analysis methods can also affect results.

Standardized testing protocols and clinically validated reference ranges are therefore essential.

Emerging molecular biomarkers offer promising opportunities for improving the diagnosis of infectious diseases.

Pathogen nucleic acids, microbial cell-free DNA, host cytokines, microRNAs, gene-expression signatures, proteins, and metabolic profiles can provide complementary information about infection.

The integration of pathogen- and host-derived biomarkers may improve diagnostic accuracy and allow earlier clinical decision-making.

Advanced sequencing and multi-omics technologies are likely to expand the range of detectable molecular signatures.

Further validation, standardization, and integration with clinical data will be necessary before many emerging biomarkers can become routine diagnostic tools.

1. Lippi G, Becan-McBride K, Behúlová D, et al. Preanalytical quality improvement: in quality we trust. Clinical Chemistry and Laboratory Medicine. 2013;51:229–241.
2. Deurenberg RH, Bathoorn E, Chlebowicz MA, et al. Application of next generation sequencing in clinical microbiology and infection prevention. Journal of Biotechnology. 2017;243:16–24.
3. Wilson MR, Naccache SN, Samayoa E, et al. Actionable diagnosis of neuroleptospirosis using metagenomic next-generation sequencing. New England Journal of Medicine. 2019;380:240–249.
4. Chiu CY, Miller SA. Clinical metagenomics. Nature Reviews Genetics. 2019;20:341–355.
5. Simner PJ, Miller S, Carroll KC. Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases. Clinical Infectious Diseases. 2018;66:778–788.
6. Liesenfeld O, Lehman L, Hunfeld KP, Kost G. Molecular diagnosis of sepsis: new aspects and recent developments. European Journal of Microbiology and Immunology. 2014;4:1–25.
7. Sweeney TE, Shidham A, Wong HR, Khatri P. A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation. Critical Care Medicine. 2015;43:1093–1100.
8. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews. 2017;10:CD007498.
9. Witwer KW, Halushka MK. Toward the promise of microRNAs as minimally invasive biomarkers for cancer. Journal of Clinical Investigation. 2016;126:2578–2585.
10. Filkins LM, O'Toole GA. Cystic fibrosis lung infections: polymicrobial, complex, and hard to treat. PLoS Pathogens. 2015;11:e1005258.